4NK3

Amp-c beta-lactamase (pseudomonas aeruginosa) in complex with mk-7655

Summary for 4NK3

• Entry DOI: 10.2210/pdb4nk3/pdb
• Descriptor: Beta-lactamase, (2S,5R)-1-formyl-N-(piperidin-4-yl)-5-[(sulfooxy)amino]piperidine-2-carboxamide (3 entities in total)
• Functional Keywords: hydrolase, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
• Biological source: Pseudomonas aeruginosa
• Cellular location: Periplasm (By similarity): P24735
• Total number of polymer chains: 1
• Total formula weight: 41374.71

Authors

Scapin, G.,Lu, J.,Fitzgerald, P.M.D.,Sharma, N. (deposition date: 2013-11-12, release date: 2014-02-19, Last modification date: 2024-11-27)

Primary citation

Blizzard, T.A.,Chen, H.,Kim, S.,Wu, J.,Bodner, R.,Gude, C.,Imbriglio, J.,Young, K.,Park, Y.W.,Ogawa, A.,Raghoobar, S.,Hairston, N.,Painter, R.E.,Wisniewski, D.,Scapin, G.,Fitzgerald, P.,Sharma, N.,Lu, J.,Ha, S.,Hermes, J.,Hammond, M.L.
Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin().
Bioorg.Med.Chem.Lett., 24:780-785, 2014

PubMed Abstract: β-Lactamase inhibitors with a bicyclic urea core and a variety of heterocyclic side chains were prepared and evaluated as potential partners for combination with imipenem to overcome class A and C β-lactamase mediated antibiotic resistance. The piperidine analog 3 (MK-7655) inhibited both class A and C β-lactamases in vitro. It effectively restored imipenem's activity against imipenem-resistant Pseudomonas and Klebsiella strains at clinically achievable concentrations. A combination of MK-7655 and Primaxin® is currently in phase II clinical trials for the treatment of Gram-negative bacterial infections.

PubMed: 24433862
DOI: 10.1016/j.bmcl.2013.12.101

Experimental method

X-RAY DIFFRACTION (1.9 Å)